Agilent Technologies Inc. (NYSE: A) and Sera Prognostics Inc., a womenâ€™s health company, today announced a strategic partnership to develop proteomic assays for the early prediction of pregnancy complications.
Sera Prognostics is currently developing a novel test for the early prediction of preterm birth risk using advanced proteomic science. Agilent is a leading provider of a wide range of analytical instrumentation, including liquid chromatography, mass spectrometry and automation systems.
â€śBy providing pivotal information to physicians, Seraâ€™s preterm birth predictor is designed to address an unmet medical need for a reliable, early risk assessment that has the potential to help significantly improve the health of mothers and newborns, while materially reducing the costs of care,â€ť said Gregory C. Critchfield, M.D., M.S., chairman and chief executive officer of Sera Prognostics. â€śOur partnership with Agilent provides Sera with access to advanced and innovative technologies designed to deliver on the promise of personalized medicine.â€ť
â€śAgilent and Sera Prognostics share the vision of applying the power of advanced proteomic technologies to address meaningful medical challenges,â€ť said Yvonne Linney, VP and general manager of Agilentâ€™s Life Science Solutions Division. â€śAgilent instrumentation is at the forefront of driving high-throughput workflows for sample preparation and mass-spec analysis that is critical in the field of proteomics.â€ť
As part of the partnership, Sera Prognostics purchased multiple Agilent 1290 Infinity ultra high-performance liquid chromatography systems, 6490 iFunnel triple quadrupole mass spectrometry systems and 1260 Infinity LC systems with ultraviolet detectors and is adapting Agilentâ€™s automated sample-preparation technologies for production.
The partners will develop high-throughput workflows for sample preparation and mass-spectrometry analysis. To meet the demands of high-volume testing, Sera Prognostics expects to leverage Agilentâ€™s novel automated sample-prep technology and other automation, including the AssayMAP Bravo and RapidFire fast liquid chromatography together with ultra-sensitive ion funnel triple quadrupole mass spectrometry.
About Sera Prognostics, Inc.
Sera Prognostics is a private biotechnology company developing novel diagnostic tests designed for the early prediction of preterm birth and other pregnancy complications, so that personalized, effective care can be given. These innovative tests have the potential of improving the health of both mothers and infants. In November 2011, Sera completed a Series A financing round of $19.3 million to develop its ProNid preterm birth predictor. The company has assembled a strong management team and board of directors with significant clinical development and women's health-care diagnostic experience. Sera is currently completing the worldâ€™s largest clinical biomarker study focused on the validation of its ProNid test for predicting the risk of preterm birth. Sera is located in Salt Lake City, Utah. For more information, visit www.seraprognostics.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the worldâ€™s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The companyâ€™s 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive news are available at www.agilent.com/go/news.Business Wire
Last updated on: 13/02/2013